The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for blockbuster treatments and significant returns is certain, the associated risks are also notable. Many o